Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders.

Neural Regen Res · 2023 · PMC9700111 · PMID 36204844

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In another randomized phase 2 study ( NCT00976118 ), masitinib (a multi-targeted kinase inhibitor of Kit, Lyn, and PDGFR) showed a positive trend to reduce cognitive decline at 24 weeks in patients with mild to moderate AD compared to placebo.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.